| 1 |
32431543 |
10.2147/CMAR.S242903 |
2022 |
Clinicopathological Characteristics and Mutational Profiling of Adult T-Cell Lymphoblastic Lymphoma in a Chinese Population. |
JAK3 |
| 2 |
32695399 |
10.1186/s40364-020-00205-4 |
2022 |
Plasma circulating tumor DNA assessment reveals <i>KMT2D</i> as a potential poor prognostic factor in extranodal NK/T-cell lymphoma. |
JAK3 |
| 3 |
33526873 |
10.1038/s41379-021-00739-4 |
2022 |
Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. |
JAK3 |
| 4 |
34321240 |
10.1158/0008-5472.CAN-21-1027 |
2022 |
Mutant <i>Idh2</i> Cooperates with a <i>NUP98-HOXD13</i> Fusion to Induce Early Immature Thymocyte Precursor ALL. |
JAK3 |
| 5 |
34465864 |
10.1038/s41375-021-01392-1 |
2022 |
PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression. |
JAK3 |
| 6 |
34547646 |
10.1016/j.bioorg.2021.105330 |
2022 |
Design, synthesis, and biological evaluation of cyano-substituted 2,4-diarylaminopyrimidines as potent JAK3 inhibitors for the treatment of B-cell lymphoma. |
JAK3 |
| 7 |
34895266 |
10.1186/s13000-021-01173-5 |
2022 |
Clinicopathological and molecular genomic features of monomorphic epitheliotropic intestinal T-cell lymphoma in the Chinese population: a study of 20 cases. |
JAK3 |
| 8 |
34980830 |
10.1097/PAS.0000000000001859 |
2022 |
Clinicopathologic and Genetic Features of Primary T-cell Lymphomas of the Central Nervous System: An Analysis of 11 Cases Using Targeted Gene Sequencing. |
JAK3 |
| 9 |
35111674 |
10.3389/fonc.2021.790481 |
2022 |
Mutations in <i>JAK/STAT</i> and <i>NOTCH1</i> Genes Are Enriched in Post-Transplant Lymphoproliferative Disorders. |
JAK3 |
| 10 |
35253299 |
10.1002/gcc.23036 |
2022 |
CRLF2 overexpression defines an immature-like subgroup which is rescued through restoration of the PRC2 function in T-cell precursor acute lymphoblastic leukemia. |
JAK3 |
| 11 |
35395675 |
10.1093/carcin/bgac034 |
2022 |
Genomic profile of radiation-induced early-onset mouse B-cell lymphoma recapitulates features of Philadelphia chromosome-like acute lymphoblastic leukemia in humans. |
JAK3 |
| 12 |
35411095 |
10.1038/s41375-022-01558-5 |
2022 |
JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. |
JAK3 |
| 13 |
35511669 |
10.3324/haematol.2021.280349 |
2022 |
Deregulated JAK3 mediates growth advantage and hemophagocytosis in extranodal nasal-type natural killer/T-cell lymphoma. |
JAK3 |
| 14 |
35551151 |
10.1097/PAS.0000000000001914 |
2022 |
Targeted Next-generation Sequencing Reveals a Wide Morphologic and Immunophenotypic Spectrum of Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma. |
JAK3 |
| 15 |
35685993 |
10.21147/j.issn.1000-9604.2022.02.03 |
2022 |
Genomic landscape of T-cell lymphoblastic lymphoma. |
JAK3 |
| 16 |
35708139 |
10.3324/haematol.2022.281226 |
2022 |
Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome. |
JAK3 |
| 17 |
35734596 |
10.3389/fonc.2022.846573 |
2022 |
The Clinical Characteristics and Prognosis of AYA and Older Adult ETP-ALL/LBL: A Real-World Multicenter Study in China. |
JAK3 |
| 18 |
35803438 |
10.1016/j.taap.2022.116156 |
2022 |
1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-(2-(dimethylamino)ethyl)imidazolidin-2-one (ZX-42) inhibits cell proliferation and induces apoptosis via inhibiting ALK and its downstream pathways in Karpas299 cells. |
JAK3 |
| 19 |
35882439 |
10.1182/bloodadvances.2022007541 |
2022 |
Genetic and immunohistochemical profiling of NK/T-cell Lymphomas reveals prognostically relevant BCOR-MYC association. |
JAK3 |
| 20 |
35920299 |
10.1096/fj.202200061RR |
2022 |
Mcm2 hypomorph leads to acute leukemia or hematopoietic stem cell failure, dependent on genetic context. |
JAK3 |
| 21 |
23136597 |
10.3892/etm_00000014 |
2021 |
Therapeutic effects of γ-irradiation in a primary effusion lymphoma mouse model. |
JAK3 |
| 22 |
28123872 |
10.1080/2162402X.2016.1237327 |
2021 |
IL-15 enhances the antitumor effect of human antigen-specific CD8<sup>+</sup> T cells by cellular senescence delay. |
JAK3 |
| 23 |
31049933 |
10.1111/bjd.18098 |
2021 |
Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-κB and nuclear factor of activated T cells pathways. |
JAK3 |
| 24 |
31822801 |
10.1038/s41379-019-0415-5 |
2021 |
Mutational profile and EBV strains of extranodal NK/T-cell lymphoma, nasal type in Latin America. |
JAK3 |
| 25 |
31918398 |
10.1016/j.bioorg.2019.103542 |
2021 |
JAK3 inhibitors based on thieno[3,2-d]pyrimidine scaffold: design, synthesis and bioactivity evaluation for the treatment of B-cell lymphoma. |
JAK3 |
| 26 |
32558259 |
10.1111/jcmm.15362 |
2021 |
Tubulosine selectively inhibits JAK3 signalling by binding to the ATP-binding site of the kinase of JAK3. |
JAK3 |
| 27 |
32843425 |
10.1101/mcs.a004994 |
2021 |
Failure of tofacitinib to achieve an objective response in a <i>DDX3X-MLLT10</i> T-lymphoblastic leukemia with activating <i>JAK3</i> mutations. |
JAK3 |
| 28 |
33376237 |
10.1038/s41392-020-00331-3 |
2021 |
Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma. |
JAK3 |
| 29 |
33466582 |
10.3390/cancers13020280 |
2021 |
JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL). |
JAK3 |
| 30 |
34258755 |
10.1111/bjh.17639 |
2021 |
Characteristics of genetic alterations of peripheral T-cell lymphoma in childhood including identification of novel fusion genes: the Japan Children's Cancer Group (JCCG). |
JAK3 |
| 31 |
34391330 |
10.5070/D327754365 |
2021 |
Significant improvement of dermatitis herpetiformis with tofacitinib. |
JAK3 |
| 32 |
34623329 |
10.1172/JCI152464 |
2021 |
To T or not to B: germline RUNX1 mutation preferences in pediatric ALL predisposition. |
JAK3 |
| 33 |
30914738 |
10.1038/s41598-019-41675-3 |
2020 |
Detection of novel fusion-transcripts by RNA-Seq in T-cell lymphoblastic lymphoma. |
JAK3 |
| 34 |
30997845 |
10.1080/10428194.2019.1594220 |
2020 |
Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. |
JAK3 |
| 35 |
31313387 |
10.1002/JLB.5RU0519-145R |
2020 |
JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy. |
JAK3 |
| 36 |
31492675 |
10.1182/blood.2019000015 |
2020 |
Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia. |
JAK3 |
| 37 |
31545408 |
10.3892/ijo.2019.4882 |
2020 |
Genome profiling revealed the activation of IL2RG/JAK3/STAT5 in peripheral T‑cell lymphoma expressing the ITK‑SYK fusion gene. |
JAK3 |
| 38 |
31570576 |
10.1073/pnas.1901382116 |
2020 |
IL-2 receptors preassemble and signal in the ER/Golgi causing resistance to antiproliferative anti-IL-2Rα therapies. |
JAK3 |
| 39 |
31773249 |
10.1007/s00428-019-02704-8 |
2020 |
Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas. |
JAK3 |
| 40 |
31799703 |
10.1111/cei.13405 |
2020 |
The IL-2RG R328X nonsense mutation allows partial STAT-5 phosphorylation and defines a critical region involved in the leaky-SCID phenotype. |
JAK3 |
| 41 |
31896782 |
10.1038/s41375-019-0697-0 |
2020 |
The clinical mutatome of core binding factor leukemia. |
JAK3 |
| 42 |
31914529 |
10.3760/cma.j.issn.0529-5807.2020.01.004 |
2020 |
[Monomorphic epitheliotropic intestinal T-cell lymphoma: a clinicopathological analysis of twelve cases]. |
JAK3 |
| 43 |
31992840 |
10.1038/s41375-019-0685-4 |
2020 |
Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation. |
JAK3 |
| 44 |
32188095 |
10.3390/cancers12030702 |
2020 |
<i>STAT3</i> Mutation Is Associated with STAT3 Activation in CD30<sup>+</sup> ALK<sup>-</sup> ALCL. |
JAK3 |
| 45 |
32316399 |
10.3390/cancers12040986 |
2020 |
Identifying Genetic Lesions in Ocular Adnexal Extranodal Marginal Zone Lymphomas of the MALT Subtype by Whole Genome, Whole Exome and Targeted Sequencing. |
JAK3 |
| 46 |
32631903 |
10.1128/MCB.00189-20 |
2020 |
Janus Kinase Mutations in Mice Lacking PU.1 and Spi-B Drive B Cell Leukemia through Reactive Oxygen Species-Induced DNA Damage. |
JAK3 |
| 47 |
32922661 |
10.18632/oncotarget.27683 |
2020 |
The NKL-code for innate lymphoid cells reveals deregulated expression of NKL homeobox genes HHEX and HLX in anaplastic large cell lymphoma (ALCL). |
JAK3 |
| 48 |
33102814 |
10.1016/j.bbrep.2020.100832 |
2020 |
Cucurbitacin E and I target the JAK/STAT pathway and induce apoptosis in Sézary cells. |
JAK3 |
| 49 |
33283700 |
10.19746/j.cnki.issn.1009-2137.2020.06.001 |
2020 |
[Gene Mutation in Acute Lymphoblastic Leukemia by DNA Sequencing]. |
JAK3 |
| 50 |
27669408 |
10.1371/journal.pone.0163011 |
2019 |
Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy. |
JAK3 |
| 51 |
28356009 |
10.2174/1871520617666170327115657 |
2019 |
ECPIRM, a Potential Therapeutic Agent for Cutaneous T-Cell Lymphoma, Inhibits Cell Proliferation and Promotes Apoptosis via a JAK/STAT Pathway. |
JAK3 |
| 52 |
29187379 |
10.1182/blood-2017-07-797597 |
2019 |
Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL. |
JAK3 |
| 53 |
29262599 |
10.18632/oncotarget.21790 |
2019 |
Fusion of the genes ataxin 2 like, <i>ATXN2L</i>, and Janus kinase 2, <i>JAK2</i>, in cutaneous CD4 positive T-cell lymphoma. |
JAK3 |
| 54 |
29434279 |
10.1038/s41375-017-0004-x |
2019 |
Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma. |
JAK3 |
| 55 |
29496663 |
10.1158/2159-8290.CD-17-0583 |
2019 |
HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development. |
JAK3 |
| 56 |
29751003 |
10.1016/j.jid.2018.03.1526 |
2019 |
SATB1 in Malignant T Cells. |
JAK3 |
| 57 |
29986854 |
10.1182/bloodadvances.2018016089 |
2019 |
Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models. |
JAK3 |
| 58 |
30054295 |
10.1182/blood-2018-01-829424 |
2019 |
Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. |
JAK3 |
| 59 |
30218753 |
10.1016/j.humpath.2018.08.025 |
2019 |
Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK/T-cell lymphoma, nasal type, is associated with disease progression and prognosis. |
JAK3 |
| 60 |
30402490 |
10.1155/2018/6728128 |
2019 |
Gene Expression Profile Signature of Aggressive Waldenström Macroglobulinemia with Chromosome 6q Deletion. |
JAK3 |
| 61 |
30420593 |
10.1038/s41408-018-0138-8 |
2019 |
Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma. |
JAK3 |
| 62 |
30671064 |
10.3389/fimmu.2018.03108 |
2019 |
Loss of JAK1 Drives Innate Immune Deficiency. |
JAK3 |
| 63 |
31002364 |
10.3892/or.2019.7112 |
2019 |
JAK3/STAT3 oncogenic pathway and PRDM1 expression stratify clinicopathologic features of extranodal NK/T‑cell lymphoma, nasal type. |
JAK3 |
| 64 |
27144517 |
10.18632/oncotarget.9077 |
2018 |
Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma. |
JAK3 |
| 65 |
27329723 |
10.18632/oncotarget.10160 |
2018 |
STAT5 induces miR-21 expression in cutaneous T cell lymphoma. |
JAK3 |
| 66 |
27600764 |
10.1038/ncomms12602 |
2018 |
Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations. |
JAK3 |
| 67 |
27602765 |
10.18632/oncotarget.11796 |
2018 |
Genomic characterization of pediatric T-cell acute lymphoblastic leukemia reveals novel recurrent driver mutations. |
JAK3 |
| 68 |
27732937 |
10.18632/oncotarget.12529 |
2018 |
Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. |
JAK3 |
| 69 |
28214593 |
10.1016/j.mce.2017.02.019 |
2018 |
JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics. |
JAK3 |
| 70 |
29146136 |
10.1016/j.ejmech.2017.10.080 |
2018 |
Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma. |
JAK3 |
| 71 |
29293620 |
10.1371/journal.pone.0190468 |
2018 |
Circulating Tfh1 (cTfh1) cell numbers and PD1 expression are elevated in low-grade B-cell non-Hodgkin's lymphoma and cTfh gene expression is perturbed in marginal zone lymphoma. |
JAK3 |
| 72 |
29454012 |
10.1016/j.yrtph.2018.02.006 |
2018 |
Immunologic effects of chronic administration of tofacitinib, a Janus kinase inhibitor, in cynomolgus monkeys and rats - Comparison of juvenile and adult responses. |
JAK3 |
| 73 |
30257940 |
10.1073/pnas.1721678115 |
2018 |
PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice. |
JAK3 |
| 74 |
26854024 |
10.1038/leu.2016.13 |
2017 |
JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma. |
JAK3 |
| 75 |
27151989 |
10.3324/haematol.2016.143875 |
2017 |
Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia. |
JAK3 |
| 76 |
27164089 |
10.3390/ijms17050683 |
2017 |
Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses. |
JAK3 |
| 77 |
27174491 |
10.1038/leu.2016.83 |
2017 |
MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia. |
JAK3 |
| 78 |
27297789 |
10.1182/blood-2016-01-690701 |
2017 |
EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma. |
JAK3 |
| 79 |
27997540 |
10.1371/journal.pmed.1002200 |
2017 |
IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study. |
JAK3 |
| 80 |
28009988 |
10.18632/oncotarget.14032 |
2017 |
A neutralized human LMP1-IgG inhibits ENKTL growth by suppressing the JAK3/STAT3 signaling pathway. |
JAK3 |
| 81 |
28245838 |
10.1186/s13045-017-0431-1 |
2017 |
Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. |
JAK3 |
| 82 |
28284718 |
10.1016/j.ajpath.2017.01.004 |
2017 |
Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type. |
JAK3 |
| 83 |
28315597 |
10.1016/j.ejmech.2017.03.001 |
2017 |
Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor. |
JAK3 |
| 84 |
28359267 |
10.1186/s12885-017-3233-5 |
2017 |
Aberrant expression of ALK and EZH2 in Merkel cell carcinoma. |
JAK3 |
| 85 |
28424246 |
10.1084/jem.20160894 |
2017 |
Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2. |
JAK3 |
| 86 |
28671688 |
10.1038/ng.3909 |
2017 |
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. |
JAK3 |
| 87 |
25146434 |
10.3109/10428194.2014.957204 |
2016 |
Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia. |
JAK3 |
| 88 |
25915535 |
10.18632/oncotarget.3837 |
2016 |
Malignant T cells express lymphotoxin α and drive endothelial activation in cutaneous T cell lymphoma. |
JAK3 |
| 89 |
25961555 |
10.2741/4369 |
2016 |
ALK-mediated post-transcriptional regulation: focus on RNA-binding proteins. |
JAK3 |
| 90 |
25980440 |
10.18632/oncotarget.3776 |
2016 |
Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type. |
JAK3 |
| 91 |
26169955 |
10.1016/j.exphem.2015.06.303 |
2016 |
A new ATL xenograft model and evaluation of pyrrolidine dithiocarbamate as a potential ATL therapeutic agent. |
JAK3 |
| 92 |
26206799 |
10.3324/haematol.2015.130179 |
2016 |
Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia. |
JAK3 |
| 93 |
26208852 |
10.1186/s13045-015-0192-7 |
2016 |
JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia. |
JAK3 |
| 94 |
26244872 |
10.18632/oncotarget.4111 |
2016 |
Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma. |
JAK3 |
| 95 |
26269126 |
10.1186/s12885-015-1586-1 |
2016 |
Somatic drivers of B-ALL in a model of ETV6-RUNX1; Pax5(+/-) leukemia. |
JAK3 |
| 96 |
26379152 |
10.1097/PAS.0000000000000503 |
2016 |
Primary CNS T-cell Lymphomas: A Clinical, Morphologic, Immunophenotypic, and Molecular Analysis. |
JAK3 |
| 97 |
26408659 |
10.1158/2159-8290.CD-15-0892 |
2016 |
Infection Exposure is a Causal Factor in B-cell Precursor Acute Lymphoblastic Leukemia as a Result of Pax5-Inherited Susceptibility. |
JAK3 |
| 98 |
26415585 |
10.1038/ncomms9470 |
2016 |
Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome. |
JAK3 |
| 99 |
26446793 |
10.1074/jbc.M115.670224 |
2016 |
Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities. |
JAK3 |
| 100 |
26536348 |
10.1371/journal.pone.0141906 |
2016 |
Concurrent Mutations in ATM and Genes Associated with Common γ Chain Signaling in Peripheral T Cell Lymphoma. |
JAK3 |
Datasets
Models
